✦ LIBER ✦

Transgenic mouse models for B-cell dominant autoimmune diseases

✍ Scribed by Masao Murakami; Tasuku Honjo

Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 471 KB
Volume: 9
Category: Article
ISSN: 0952-7915
DOI: 10.1016/s0952-7915(97)80188-4

No coin nor oath required. For personal study only.

✦ Synopsis

To study the molecular mechanism for the development of B-cell dominant autoimmune diseases, several autoantibody transgenic mouse models were established. These studies have revealed that the escape of autoreactive B cells from clonal deletion or functional inactivation (clonal anergy) alone is not enough to develop autoimmune disease. Indeed, additional factors such as infections, cytokines and the costimulatory help of T cells are required for the activation of autoreactive B cells. The requirement for activation of autoreactive clones is also shown for the development of T-cell dominant autoimmune diseases in a T-cell receptor transgenic model. These findings will clarify the two-step mechanism of autoimmune disease: appearance and activation of autoreactive lymphocytes.

📜 SIMILAR VOLUMES

B cell–ablative therapy for the treatmen

B cell–ablative therapy for the treatment of autoimmune diseases

✍ Dhavalkumar D. Patel 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB 👁 2 views

Transgenic mouse as a tool for the study

Transgenic mouse as a tool for the study of autoimmune disease: Insulin-dependent diabetes mellitus

✍ Ken-Ichi Yamamura; Miyazaki Tohru; Masashi Uno; Jun-Ichi Miyazaki 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 386 KB

New prospects for autoimmune disease the

New prospects for autoimmune disease therapy: B cells on deathwatch

✍ E. William St.Clair; Thomas F. Tedder 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 2 views

Dr. St.Clair has served on the advisory boards of Genentech, Cellective Therapeutics (now owned by MedImmune), and Human Genome Sciences. Dr. Tedder has Tedder has received consulting fees (more than $10,000 per year) from Cellective Therapeutics (now owned by MedImmune), has given expert testimony

Transgenic mouse models for the chronic

Transgenic mouse models for the chronic hepatitis B surface antigen carrier state: Transfection a deux

✍ Adrian M. Di Bisceglie; Jay H. Hoofnagle 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

In an attempt to establish a model of the healthy carrier state in hepatitis B virus (HBV) infections, transgenic mice expressing HBV genes were produced. Fertilized one-cell eggs were microinjected with subgenomic fragments of HBV DNA containing the coding regions for the HBV surface antigen (HBsAg

Comparable processing ofβ-lactoglobulin

Comparable processing ofβ-lactoglobulin pre-mRNA in cell culture and transgenic mouse models

✍ Donofrio, G. ;Clark, A. J. ;Whitelaw, C. B. A. ;Donofrio, G. ;Bignetti, E. 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 650 KB

Decreased cerebral perfusion correlates

Decreased cerebral perfusion correlates with increased BOLD hyperoxia response in transgenic mouse models of sickle cell disease

✍ Richard P. Kennan; Sandra M. Suzuka; Ronald L. Nagel; Mary E. Fabry 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 627 KB

## Abstract Neurological complications such as stroke are known consequences of sickle cell disease (SCD). In order to improve methods for the evaluation of stroke risk in SCD, MRI was used to evaluate cerebrovascular function in transgenic mouse models of human SCD. It is hypothesized that oxygen‐